• If you are wondering whether Cigna Group's current share price reflects its underlying worth, the recent performance gives you plenty to question and analyse.
• At a last close of US$261.49, the stock has seen a 2.6% decline over the last 7 days, a 6.7% decline over 30 days, a 6.3% decline year to date, and a 16.7% decline over the past year, while the 3 year and 5 year returns sit at 5.6% and 15.6% respectively.
• These moves have played out as investors continue to assess Cigna Group's position in the broader healthcare space and how its business mix fits current sentiment. Recent coverage has focused on how the stock's pullback contrasts with its multi year return profile and what that might imply for today's pricing.
• Simply Wall St's valuation model currently gives Cigna Group a value score of 6 out of 6. The rest of this article will walk through the main valuation approaches behind that score, and then finish with a way to look beyond the numbers to understand what that valuation might really mean for you.

Approach 1: Cigna Group Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes expected future cash flows, then discounts them back to today to estimate what the business could be worth right now.

For Cigna Group, the latest twelve month free cash flow stands at about $8.0b. Analysts have provided explicit forecasts out to 2030, with Simply Wall St extending these to a full 10 year path using its 2 Stage Free Cash Flow to Equity framework. By 2035, the extrapolated free cash flow used in the model is just over $11.0b, with each year in between discounted back to today using a required return.

Adding those discounted cash flows together, the DCF model arrives at an estimated intrinsic value of about $891.23 per share. Compared with the recent share price of US$261.49, this indicates Cigna Group trades at a 70.7% discount to that DCF estimate. This suggests the market price is well below the value implied by these cash flow projections.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cigna Group is undervalued by 70.7%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Approach 2: Cigna Group Price vs Earnings

For profitable companies, the P/E ratio is a useful way to relate what you are paying for each share to the earnings that business is currently generating. It gives you a quick sense of how the market is weighing earnings against factors like growth expectations and perceived risk.

In general, higher expected earnings growth and lower perceived risk can support a higher P/E ratio, while lower growth expectations or higher risk usually point to a lower, more cautious multiple. So the question is not whether a P/E is high or low in isolation, but whether it lines up with what the company’s profile might justify.

Cigna Group currently trades on a P/E of 11.57x, compared with a Healthcare industry average of about 21.22x and a peer group average of 28.00x. Simply Wall St’s “Fair Ratio” for Cigna Group is 31.96x, which is its proprietary view of what the P/E could be given factors such as earnings growth, industry, profit margins, market cap and risk profile. This Fair Ratio can be more informative than a simple peer or industry comparison because it is tailored to Cigna Group’s specific characteristics. With the Fair Ratio well above the current 11.57x, the P/E based view points to the shares looking undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Cigna Group Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a clear story about Cigna Group to your numbers such as fair value, and your assumptions for future revenue, earnings and margins. The Simply Wall St Community page lets you compare those views in an easy tool that millions of investors already use. You can see how each Narrative links a business story to a forecast and then to a fair value, and keep that view updated automatically when new information like news, earnings or updated analyst targets comes in. For Cigna Group, you might see one Narrative that leans toward the higher analyst price target of US$428 because it places more weight on onsite care expansion, share repurchases and the current fair value estimate of about US$338.80. Another Narrative might sit closer to the lowest target of US$300 because it focuses more on risks such as PBM regulation, affordability pressures and client concentration. By comparing each Narrative’s fair value to today’s share price, you can decide how that lines up with your own stance on whether to wait, add, or reduce exposure.

Do you think there's more to the story for Cigna Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.